Rhonda Patrick· PhD
If we can combine that kind of analysis with the kind of methylation analysis that Horvath has developed, then I think we'll be able to ask some very intriguing questions about the predictability of age-related ill health.
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
If we can combine that kind of analysis with the kind of methylation analysis that Horvath has developed, then I think we'll be able to ask some very intriguing questions about the predictability of age-related ill health.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.